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Abstract
The archetypal imaging characteristics of meningiomas are among the most stereotypic of all central nervous 
system (CNS) tumors. In the era of plain film and ventriculography, imaging was only performed if a mass was 
suspected, and their results were more suggestive than definitive. Following more than a century of technological 
development, we can now rely on imaging to non-invasively diagnose meningioma with great confidence and pre-
cisely delineate the locations of these tumors relative to their surrounding structures to inform treatment planning. 
Asymptomatic meningiomas may be identified and their growth monitored over time; moreover, imaging rou-
tinely serves as an essential tool to survey tumor burden at various stages during the course of treatment, thereby 
providing guidance on their effectiveness or the need for further intervention. Modern radiological techniques are 
expanding the power of imaging from tumor detection and monitoring to include extraction of biologic informa-
tion from advanced analysis of radiological parameters. These contemporary approaches have led to promising 
attempts to predict tumor grade and, in turn, contribute prognostic data. In this supplement article, we review 
important current and future aspects of imaging in the diagnosis and management of meningioma, including con-
ventional and advanced imaging techniques using CT, MRI, and nuclear medicine.
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Although reports on tumors of meningeal attachment existed 
in the nineteenth century, the canonization of meningioma as 
a distinct entity occurred upon the publication of Cushing and 
Eisenhardt’s seminal work, “Meningiomas: Their Classification, 
Regional Behaviour, Life History, and Surgical End Results.”1 
Strikingly though, the discussion of imaging is relatively 
absent in this monumental monograph, save for infrequent 
radiographs, given the central role that imaging plays today in 
the diagnosis and management of meningiomas.
Of the pivotal developments in our understanding of 
intracranial meningiomas—including evolution of surgi-
cal technique, a role for radiation, and a resurgent inter-
est in their biology—perhaps none has been as central as 
the application of imaging to their study, beginning with 
the first radiological report of a meningioma in a living 
patient who presented with hemiparesis, hemianopia, and 
headaches in 1902 by radiograph.2 The radiographic fea-
tures of meningioma were expanded in an analysis of 95 
patients operated by Harvey Cushing, noting the cardinal 
features of vascularity, osteomatous changes, spicule for-
mation, diffuse thickening, enlargement of the meningeal 
artery channel, and calcification.3 Walter Dandy integrated 
the role of mass effect exerted by tumors with their radio-
graphic stigmata with his introduction of ventriculography 
and pneumoencephalography, wherein directional distor-
tion of the ventricular system as cast by injected air aided in 
meningioma localization. Moreover, Dandy emphasized the 
importance of tumor localization prior to surgery, extrapo-
lating from neurological symptoms, signs, and inferences 
derived from these early imaging modalities. This was a 
staple of cranial imaging for decades after its initial descrip-
tion, although Cushing himself was reluctant to adopt it. 
Collectively, early imaging modalities relied upon infer-
ence—Cushing noted that he assumed recurrence when 
surgical clips shifted in position on radiographs over time.
The next important development in the history of 
imaging of meningioma was the application of cerebral 
angiography to the radiographic diagnosis of meningi-
oma—the marriage of intra-arterial dye injection to exist-
ing methods of radiography. Moniz introduced the concept 
of angiography in 1927 and was the first to describe the 
angiographic findings in intracranial meningioma with 
colleagues 2 years later.4 List and Hodges reported on the 
first large series of angiography in brain tumors, and high-
lighted concurrent contribution by both extracranial and 
intracranial circulations with an intervening intratumoral 
vascular blush as being pathognomonic for meningioma, 
when present.5 Understanding the coaptation of vascu-
lar feeders by meningioma further inspired clinicians to 
diminish surgical risk and blood loss through preopera-
tive embolization of critical feeders, transforming angiog-
raphy from a diagnostic tool to an interventional strategy. 
Angiography, in either catheter-based or non-invasive 
form, is routinely employed to clarify important anatomy 
of adjacent arterial and venous structures.
The introduction of CT by Sir Godfrey Hounsfield and 
MRI by Paul Lauterbur in 1973 launched the central role 
of imaging as we know it today in the diagnosis and man-
agement of meningiomas.6,7 These powerful modalities, 
coupled with the administration of intravenous contrast, 
elucidated the extra-axial anatomic origin of meningi-
omas, their patterns of growth, dural spread frequently far 
beyond the limits of the tumor bulk, variable involvement 
of adjacent bone with either lytic or hyperostotic changes, 
and stereotypic involvement and deflection of neurovas-
cular structures. The unique resolution of meningioma 
appearance and involvement of neighboring tissue by CT 
and MRI spurred parallel developments in preoperative 
planning and surgical techniques, sharpening awareness 
of operative risk and allowing greater definitive resection 
of meningioma from multiple compartments. Additionally, 
important arterial and venous relationships could now be 
studied in greater detail with CT or MR angiography.8
The radiological diagnosis of meningioma is typically 
certain on CT and MRI evaluation. However, differenti-
ating residual or recurrent tumor from postsurgical or 
radiation treatment changes may prove challenging on 
occasion. In these instances, modern imaging modalities 
have exploited specific attributes of meningioma biology: 
for example, nuclear scintigraphy or positron emission 
tomography (PET) may detect radiolabeled octreotide, 
a somatostatin agonist, and its binding to tumor-specific 
somatostatin receptors (eg, SSTR II).
The routine availability of CT and now MRI has provided 
a reliable non-invasive means to track tumor growth, allow-
ing the derivation of the natural history of meningioma 
in cases where asymptomatic patients are followed with 
imaging over time. While in the early days of neurosur-
gery, imaging was used to verify and localize a tumor after 
patient presentation with a neurologic symptom, tumors 
are now frequently incidentally discovered. The decision 
to treat or follow the presumed meningioma with serial 
imaging has fueled interest in predicting tumor behavior—
and even grade—from imaging features alone. This forces 
a critical evaluation of which patients need treatment if 
tumors are small and asymptomatic at the time of initial 
identification. This has led to scrutiny of specific features 
on conventional MRI as well as advanced imaging modali-
ties like MR spectroscopy or PET in order to infer tumor 
behavior from imaging characteristics.
Applications of advanced computational methods like 
machine learning and radiomics to existing imaging data 
hold promise in acquiring such biologic data as meningi-
oma grade, the most powerful predictor of tumor behavior 
and recurrence available to date, or to improve prognosti-
cation independently of grade.9 Below, we review import-
ant salient current and future aspects of imaging in the 
diagnosis and management of meningioma.
Conventional Imaging Features of 
Meningiomas
Meningiomas usually occur as intracranial extra-axial 
masses attached to the dura mater.10 While the typical 
appearance is of a mass with a broad-based dural attach-
ment, meningiomas can also extend along a wide expanse 
of dura in a sheet-like appearance (en plaque meningioma).
Histologically, meningiomas arise from meningoepi-
thelial cells, also known as arachnoid cap cells. As such, 
meningiomas most commonly occur where these cells 
are most numerous, such as where the arachnoid granu-
lations are concentrated along the dural venous sinuses.10 
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Of all intracranial meningiomas, approximately half are 
located along the skull base, 40% along the calvarial con-
vexity, 10% along the falx and parasagittal region, and a 
small fraction within the ventricle or across multiple loca-
tions.11,12 The majority of meningiomas are considered 
primarily intradural tumors.13,14 However, 1–2% of men-
ingiomas are extradural and arise in locations other than 
the dura, including within the calvarium, scalp, paranasal 
sinuses, nasopharynx, neck, and skin with rarer locations 
also reported.13,14 While the locations of primary extradural 
meningiomas vary, two-thirds are made up of primary 
intraosseous meningiomas, which are postulated to arise 
from arachnoid cap cells that become caught between cra-
nial sutures during birth.13,14 Meningiomas are most often 
solitary, with one series demonstrating multiple meningi-
omas on CT in 8.9% of patients.15
CT Features
Typical diagnostic features are found on CT in 72–85% of 
cases, including a sharply circumscribed lobular mass 
with a broad-based dural attachment.10 On unenhanced 
CT, meningiomas typically appear as homogeneous 
and hyperdense extra-axial masses, which demonstrate 
homogeneous enhancement following contrast admin-
istration.10,16 Furthermore, meningiomas are classically 
associated with intratumoral calcification as befitting their 
slow growth rate, although specific subtypes may trigger 
dystrophic or metaplastic calcification as well, which lends 
a speckled hyperdense appearance on CT seen in 15–20% 
of cases (Figs. 1, 2).17 CT also best demonstrates the bony 
changes sometimes associated with meningiomas. These 
changes can include hyperostosis, osteolysis, and, in the 
setting of an anterior skull base meningioma, pneumosi-
nus dilatans. Hyperostosis, which is the most commonly 
associated bony finding, manifests as bony thickening on 
CT and is seen in up to 25–49% of meningiomas, with the 
convexity and sphenoid wing the most common locations 
(Fig. 3).18 Hyperostosis may be reactive or associated with 
osseous tumor invasion; the differentiation may be difficult 
on imaging, but strong enhancement within hyperostotic 
bone makes tumor invasion more likely.
MRI Features
On MRI, meningiomas are usually hypo- to isointense rela-
tive to cerebral cortex on T1-weighted sequences and iso- 
to hyperintense on T2-weighted sequences (Fig. 1, 2).10,19 
As on CT, most meningiomas enhance avidly on MRI, and 
nearly all enhance at least in part, even if heavily calci-
fied. The presence of intratumoral cysts, hemorrhage, or 
necrosis can produce a heterogeneous appearance and 
may be associated with more aggressive behavior of the 
tumor. A dural tail is seen on postcontrast imaging in up 
to 72% of meningiomas.16 While a dural tail may repre-
sent reactive dural changes, one study found that nearly 
two-thirds of dural tails were invaded by tumor cells.20,21 
Intraoperatively, microscopic spread of tumor cells may 
also extend beyond the apparent dural tail on imaging. Yet 
despite the well-known association between dural tails and 
meningiomas, the sign is not specific, as other dural neo-
plasms can also demonstrate this finding.16 Nevertheless, 
this feature is useful in confirming the extra-axial loca-
tion of a large meningioma that is inseparable from brain 
and in distinguishing meningiomas from other extra-axial 
tumors such as schwannomas and pituitary adenomas that 
typically do not exhibit dural tails.
In diffusion-weighted imaging (DWI), the apparent diffu-
sion coefficient (ADC) values of meningiomas are variable, 
though ADC may be relatively low, particularly in higher 
grades but also in grade I meningiomas (Supplementary 
Fig.  1).15 On MR spectroscopy, elevated choline and ala-
nine levels and diminished N-acetylaspartate (NAA) levels 
are anticipated; elevated alanine is relatively specific for 
A B C
Fig. 1 (A) Noncontrast CT, (B) T1-weighted gadolinium-enhanced MRI, and (C) T2-weighted MRI of a partially calcified right falcine meningioma.
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A B
C D
Fig. 3 Noncontrast CT and T1-weighted gadolinium-enhanced MRI demonstrating (A, B) a grade I meningioma with profound hyperostosis and 
extracalvarial enhancing tumor, and (C, D) a grade III meningioma with lytic erosion of adjacent bone from tumor invasion.
A B C D
Fig. 2 (A) Noncontrast CT shows an extra-axial mass with a low-density CSF cleft (arrow) between the mass and adjacent right frontal lobe. 
(B) MRI T2-weighted image shows an intermediate signal mass with a CSF cleft (arrow). Gadolinium-enhanced MRI in (C) axial and (D) coronal 
planes demonstrates avid enhancement within the mass and a dural tail sign (arrowhead).
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meningioma but can be difficult to identify.22,23 Perfusion 
imaging will generally reveal high relative cerebral blood 
flow (rCBF) and relative cerebral blood volume (rCBV) 
(Supplementary Fig.  1), although substantial gadolinium 
leakage with the dynamic susceptibility contrast (DSC) 
technique confounds rCBV quantitation. Less than 50% 
return to baseline of signal intensity after gadolinium bolus 
injection with DSC is described with meningiomas,24,25 
though this percent signal recovery is technique depend-
ent (eg, dependent upon gadolinium preload use, some 
pulse sequence parameters, and software leakage correc-
tion). Arterial spin labeling (ASL) perfusion has also shown 
increased rCBF in meningiomas, particularly the angi-
omatous histological subtype,26,27 while dynamic contrast 
enhanced (DCE) MR permeability imaging parameters 
did not reliably predict meningioma microvascularization 
parameters in another study.28
As meningiomas grow larger, they demonstrate inward 
displacement of the underlying brain parenchyma.10 MRI 
helps delineate the extra-axial nature of the tumor, often 
revealing a CSF cleft between the mass and the brain 
which appears as a T2-weighted crescent. Such clefts can 
be absent, however, particularly when higher-grade men-
ingiomas invade the brain. Although most meningiomas 
demonstrate typical imaging characteristics, approxi-
mately 15% of benign meningiomas are multiple or dem-
onstrate features such as tumor necrosis, cystic change, 
hemorrhage, and fatty infiltration.29
Edema in adjacent brain is present with slightly over half 
of meningiomas, and this phenomenon does not correl-
ate well with tumor size.30,31 While atypical and malignant 
meningiomas may cause edema by invading the brain, 
World Health Organization (WHO) grade I  meningiomas 
not infrequently have peritumoral brain edema without 
brain invasion. There are various proposed etiologies to 
account for this edema, including compressive ische-
mia with compromise of the blood–brain barrier, vascular 
shunting due to parasitization of pial microvessels, mech-
anical venous obstruction, elevated hydrostatic pressure 
within the tumor, as well as secretory-excretory phenom-
ena within the tumor cells.17,32,33 As such, peritumoral brain 
edema does not reliably distinguish between benign and 
atypical or malignant meningiomas.
Vasculature
Given their vascular nature, flow voids or enhancing ves-
sels are commonly seen within and around the periphery 
of meningiomas on MRI and contrast enhanced CT. Nearly 
three-quarters of meningiomas receive their primary vas-
cular supply from dural vessels, although they may also 
parasitize the pial supply from the carotid or vertebrobasilar 
circulation.17 The blood supply to meningiomas character-
istically includes a prominent central vascular pedicle from 
which smaller vessels radiate in a “spoke wheel”–like pat-
tern and the surface is often supplied by a peripheral plexus 
of pial vessels.17 On conventional angiography, meningi-
omas usually demonstrate hypervascularity and a promi-
nent tumor blush with delayed washout.10,16 Meningiomas 
may displace, encase and narrow adjacent vessels, or 
sometimes invade or occlude dural venous sinuses (Fig. 4).
Differential Diagnosis
Meningiomas account for over a third of all primary CNS 
tumors and over half of nonmalignant CNS tumors, and pre-
dominate among extra-axial lesions.34 Despite this preva-
lence, broad differential diagnoses of meningioma exist, 
including dural-based metastasis (eg, from lung, breast, or 
prostate primaries), lymphoma and leukemia (ie, granulocytic 
sarcoma), solitary fibrous tumor, and hemangiopericytoma 
(now considered within the solitary fibrous tumor spectrum). 
Enhancing dural masses may be seen with sarcoidosis and 
tuberculosis but are often multiple (Fig. 5). Idiopathic hyper-
trophic pachymeningitis, extranodal sinus histiocytosis,35 and 
immunoglobulin G4–related disease can cause a diffuse thick-
ening of the dura which could be occasionally confused with 
en plaque or multiple meningiomas.16 Imaging features which 
distinguish meningioma mimics from meningioma itself 
can include homogeneous T2 hypo- or hyperintensity in the 
tumor, adjacent osseous destruction, leptomeningeal or pial 
extension, and absence of a dural tail.36
Molecular Imaging for Meningioma
PET is an imaging modality capable of providing biochem-
ical and physiologic data about a tumor.37 The most widely 
used radiopharmaceutical in PET imaging is 2-[18F]-fluoro-
2-deoxy-D-glucose (18F-FDG), which is a glucose analog 
actively transported into metabolically active cells.37 FDG-
PET has been used in patients with primary brain tumors 
for tumor grading, prognosis, and differentiating recur-
rent tumor from radiation necrosis.38 However, the high 
physiological FDG uptake in the cerebral cortex as well as 
the accumulation of FDG in inflammatory processes ham-
per the diagnostic accuracy of FDG-PET in brain tumors.39 
Therefore, different and more specific radioligands have 
been proposed for brain tumor diagnostics.
Meningiomas are known to have increased somatostatin 
receptor II (SSTR II) expression in almost all cases.40,41 
Radiolabeled SSTR ligands are increasingly used in PET 
imaging. The high specific binding to the SSTR in meningi-
oma, as well as the very low uptake in adjacent structures 
like bone or brain tissue, the latter due to the inability of 
these tracers to cross the blood–brain barrier, result in a 
very high tumor-to-background contrast. This is of special 
interest in those cases with low CT or MR contrast due to 
osseous infiltration or in skull base meningiomas, where 
the exact delineation is often very challenging.42,43
Recent studies revealed a higher sensitivity of PET with 
SSTR ligands labeled with gallium-68 (Ga-68) compared 
with contrast enhanced MRI, which detected only 171 out 
of 190 (92%) of the meningiomas that were revealed by 
PET/CT.44 Thus, SSTR-PET is useful for differential diag-
nosis—for instance, in discriminating optic sheath men-
ingioma.45 Initial data also demonstrated that SSTR-PET 
enables a more exact tumor delineation, especially in 
those tumors with limited MR contrast because of their 
localizations, such as at the skull base, falcine area, orbit, 
as well as sagittal and cavernous sinus or due to transos-
seous growth (Supplementary Fig. 2).46 For the detection 
of osseous involvement, a higher sensitivity of SSTR-PET 
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compared with MRI (98.5% vs 53.7%) but only a slightly 
decreased specificity (86.7% vs 93.3%) were confirmed in 
a recent study. Interestingly, intraosseous meningioma 
involvement as assessed with SSTR-PET was significantly 
larger than in contrast enhanced MRI alone (P < 0.001) and 
comparable for the extraosseous part of transosseous 
meningiomas (P  =  0.636) and for extraosseous meningi-
omas (P = 0.132).47 In addition, SSTR-PET was shown to dif-
ferentiate between viable tumor and scar tissue by using 
semi-quantitative PET data analysis, since the semi-quan-
titative uptake value (SUV) was shown to correlate with 
SSTR II expression in immunostaining.48 While further vali-
dation is needed to confirm the utility of SSTR II imaging, 
an evidence-based recommendation for the use of molecu-
lar imaging in meningioma has been proposed recently.46
Natural History of Meningiomas
Meningiomas are generally considered slowly grow-
ing lesions, often with an indolent clinical course 
depending on the location.49 Meningiomas are often clin-
ically detected when already of large size or with increas-
ing age.34 However, with increasing availability of cranial 
imaging, incidentally discovered meningiomas are becom-
ing more frequent. While it is common practice to follow 
most asymptomatic patients by MR imaging, understand-
ing the natural history and growth dynamics are essential 
for clinical decision making, especially when histological 
analysis is not established.
The benign behavior of WHO grade I  meningioma was 
recently demonstrated by using retrospective radiocarbon 
birth dating in 12 cases, which revealed a mean tumor age of 
22.1 ± 6.5 years.50 In contrast, 2 WHO grade II meningiomas 
assessed by this method developed only 1.5  ±  0.1  years 
prior to surgical resection. Several studies have indicated 
differing growth rates and doubling times between WHO 
grade I  and WHO grade II meningiomas.51–55 In a retro-
spective evaluation of 50 meningiomas, there were signifi-
cant different presurgical annual volumetric growth rates 
between WHO grade I (1.34 cm3, range 0.07–3.26 cm3) and 
WHO grade II meningiomas (6.40  cm3, 3.61–13.29  cm3).55 
In this patient cohort, a volumetric growth rate of 3.05 cm3/
A B
C D
Fig. 4 (A, B) WHO grade I meningioma with diffuse infiltration of bone and occlusion of (C) anterior superior sagittal sinus on angiography and 
(D) MRV with venous rerouting.
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year was suggested as a threshold for a higher-grade men-
ingioma.55 Similar growth rates were found for incompletely 
resected WHO grades I and II meningiomas during follow-
up.52 The growth rates and dynamics among the group of 
benign meningiomas display a huge variability.52,56 Long-
term analyses revealed changing growth dynamics in WHO 
grade I meningioma with periods of exponential, linear, or 
no growth, whereas most atypical meningiomas display an 
exponential growth pattern.53,54,57 Although some evidence 
suggests a relationship between histological grading and 
tumor growth rate, substantial validation is limited.56
The reported natural history in cohorts of incidental and 
untreated meningiomas varies significantly and may fol-
low complex growth patterns.58–60 Volumetric growth rates 
of less than 1 cm3/year in 66% of incidental meningioma 
have been reported with a range of 0.03–2.62 cm3/year and 
a mean tumor doubling time of 21.6  years ranging from 
1.27 to 143.5 years.61 Many incidental meningiomas grow 
extremely slowly or do not grow at all, but more aggres-
sive growth patterns can occur and may display growth 
rates of up to 4.0962 or 10.3 cm3/year.58 During a minimum 
follow-up period of 10  years in 65 patients with asymp-
tomatic and untreated meningiomas, 35.4% of patients 
exhibited progression defined by >2 mm increase of any 
diameter. Based on life-table statistics, the authors calcu-
lated a 75% 15-year growth rate, indicating that the major-
ity of patients may eventually progress.63
Many patient-related factors and radiological charac-
teristics have been investigated to identify predictors of 
aggressive or clinically relevant tumor progression in 
incidental and untreated meningioma, with inconsistent 
results. Younger age (≤60 years),61,62 male sex,55 radiological 
tumor characteristics such as hyperintensity on T2-weighted 
MRI,55,57,59,61,62 absence of tumor calcification,52,55,57,58,61–63 
or presence of peritumoral edema55,62 may be associated 
with a risk for relevant meningioma progression. A greater 
degree of tumor proliferation as measured by MIB-1 index 
was reported in meningiomas presenting with peritumoral 
edema, an ambiguous brain–tumor border on T2-weighted 
MRI, and irregular tumor shape.64 The impact of meningi-
oma location on the natural history is not well understood. 
Tumor location has been evaluated as a predictor for growth 
rate; in a volumetric MRI analysis of 113 incidental meningi-
omas, non–skull base meningiomas had a higher tendency 
for progression with a significantly higher growth rate 
than skull base meningiomas.65 In contrast, 2 single center 
A B
D E
C
Fig. 5 Dural sarcoidosis mimicking en plaque meningioma. (A, B, C) Gadolinium-enhanced T1-weighted images and (D, E) T2-weighted image 
show nodular dural thickening and enhancement along the falx and tentorium. 
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studies58,62 and a meta-analysis on the published natural 
history of meningioma59 were not able to establish a link 
between location and tumor growth pattern.
As meningiomas may display different growth dynamics 
over time, the initial tumor volume may have a significant 
impact on the risk of clinically relevant progression and 
outcome. Untreated meningiomas below the size of 25 mm 
in maximum diameter tend to show a benign behavior in a 
5-year follow up period.59,62 Nevertheless, even for small 
tumors an increase in tumor size >10% is significantly 
associated with the development of clinical symptoms, 
underscoring the importance of follow-up imaging espe-
cially in the first years.59 A  weighted scoring system for 
estimating the risk of rapid growth (defined as growth rate 
>2 cm3/y) of untreated meningiomas, the Asan Intracranial 
Meningioma Scoring System (AIMSS), has been pro-
posed.57 The AIMSS is based on the categorization in 3 
tumor sizes with cutoffs at <2.5 cm and ≥4 cm maximum 
diameter. With inclusion of the known risk factors such as 
absence of calcification, presence of peritumoral edema, 
and tumor signal on T2-weighted MRI, the resulting score 
allows the attribution to a low-, intermediate-, or high-risk 
group for the probability of rapid tumor growth.57,66
Although a number of studies have been conducted to 
analyze the natural history of meningiomas, the results 
are limited due to retrospective single center study design 
with different varieties of methods in assessing the growth 
dynamics. Volumetric analysis during follow-up imaging 
is more accurate in determining changes of tumor vol-
ume than measurement of maximum tumor diameter.60,62 
Newly diagnosed and radiologically presumed menin-
giomas are best followed by MRI if there is no indication 
for surgical resection. If no other differential diagnosis is 
suspected, an initial follow-up after 6  months and then 
annually if the patient remains stable has been proposed49 
but may be individually adjusted according to known risk 
factors. Based on reported growth patterns of nontreated 
meningiomas and the European Association of Neuro-
Oncology guidelines49 for follow-up of resected WHO grade 
I meningiomas, MR imaging every 2 years after a follow-up 
period of 5 years may be reasonable. Long-term data on 
the natural history63 implicates that patients should be sub-
jected to routine surveillance imaging.
Radiographic Distinction of 
Meningioma Grade
The clinical course of patients with meningiomas is 
strongly dictated by their histopathologic grade. The 
majority of meningiomas, particularly WHO grade I men-
ingiomas, are effectively managed by complete surgical 
resection, with radiotherapy used in select cases to aug-
ment local control, especially in patients with multiple 
recurrences and medical comorbidities, or in those cases 
where surgery alone is insufficient.49 However, tumor 
recurrence remains a problem, particularly for meningi-
omas with subtotal resection, with universal recurrence for 
grade III tumors and recurrence rates of 20–75% for grade II 
meningiomas at 10 years follow-up, even after aggressive 
multimodality treatment.
Given the prognostic and therapeutic implications of 
tumor grade, specifically between benign tumors and their 
atypical/malignant counterparts, preoperative knowledge 
of tumor grade may influence patient management, includ-
ing decisions of whether to observe, operate, or administer 
adjuvant therapies, as well as facilitate patient counseling 
at an earlier stage of clinical care. Furthermore, in the con-
temporary era of routine and easily accessible imaging, 
meningiomas are increasingly diagnosed as incidental 
findings, making this differentiation all that more relevant.
In general, meningiomas can be fairly confidently diag-
nosed by MRI and CT alone, typically presenting as sharply 
circumscribed masses with a broad-based dural attach-
ment, which demonstrate homogeneous enhancement 
on postcontrast imaging.10,49 However, moving from sim-
ple diagnosis toward prediction of tumor behavior such 
as through the use of non-invasive imaging biomarkers 
would further enhance clinical decision making.9
Morphologic Features
Based on imaging morphology alone, a number of fea-
tures have been shown to be associated with more aggres-
sive or higher-grade behavior, including an indistinct 
tumor–brain interface, irregular tumor shape and margins, 
heterogeneous enhancement, large tumor size, absence of 
calcification, and the presence of peritumoral edema.64,67–69
The amalgamation of specific imaging features has also 
been combined with clinical characteristics, such as older 
age, into models capable of predicting meningiomas with 
advanced histopathologic grades.70 In addition, when ser-
ial imaging data are available, the volumetric growth rate 
of meningiomas has also been shown to correlate with 
tumor grade.51,71,72
Despite the correlation of certain morphologic features 
with advanced tumor grade, the fact remains that no feature 
is specific for atypical/malignant lesions, as similar findings 
can also be seen in low-grade tumors.73 As such, the need 
remains for additional imaging biomarkers able to comple-
ment these morphologic features in assessing tumor grade.
Diffusion Weighted/Diffusion Tensor Imaging
DWI is an MR technique sensitive to the motion of water 
molecules and which, along with ADC measurements, pro-
vides important tissue microstructural information.74 In 
biological tissue, water diffusion is highly dependent on 
the ratio of extracellular to intracellular space, with water 
diffusivity being greater in the extracellular space than 
in the intracellular space.75 As such, increased cellularity 
and a subsequent decrease in the fraction of extracellular 
space cause restriction of water diffusion.75
Histologically, atypical and malignant meningiomas 
have more compact architecture with more tightly packed 
and smaller cells with increased mitotic activity, prominent 
nuclei, and high nucleus-to-cytoplasm ratio, all of which 
are factors expected to decrease water diffusivity and thus 
presumably lead to lower ADC values.74,76,77
A number of previous studies have evaluated the ability 
of ADC values to differentiate benign from atypical/malig-
nant meningiomas, with variable conclusions.74–85 One 
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study analyzing 177 meningiomas (135 benign, 37 atypical, 
and 5 malignant) found that while the mean ADC values and 
ADC ratios of benign meningiomas were higher than those 
of atypical and malignant tumors, the difference was not 
statistically significant.77 Similar findings were observed 
by several others who reported no statistically significant 
difference in respective ADC values based on meningioma 
grade.79–81,84 Other studies, however, have found signifi-
cant differences in ADC values between benign and atyp-
ical/malignant meningiomas.74–76,78,83,85,86 The largest of 
those analyzed 138 meningiomas (106 benign, 19 atypical, 
and 13 malignant) and found the mean ADC values and 
mean normalized ADC (NADC) ratios in atypical/malig-
nant meningiomas to be significantly lower than in benign 
meningiomas.85 A number of additional studies have made 
similar findings, all showing atypical/malignant meningi-
oma subtypes to have lower ADC values.74–76,78,83,86
The variability of these findings can result from differences 
in sample size, histologic criteria, and imaging method-
ology. Studies have also assessed ADC cutoff values in this 
grading assessment.74,76 An ADC cutoff value of 0.70 × 10−3 
mm2/s provided a sensitivity for diagnosing atypical/aggres-
sive meningiomas of 29%, specificity of 94%, positive pre-
dictive value of 67%, and negative predictive value of 75%.74 
Using receiver operating characteristic curves, others found 
that the optimal ADC and NADC thresholds for differen-
tiating atypical/malignant meningiomas were 0.80  ×  10−3 
mm2/s and 0.99, respectively.76 Using these thresholds, ADC 
correctly predicted 96% of atypical/ malignant and 83% of 
benign meningiomas, and NADC correctly predicted 96% of 
atypical/malignant and all of the benign meningiomas.76
In contrast to isotropic DWI, which eliminates directional 
or anisotropic diffusion, diffusion tensor imaging (DTI) 
analyzes the 3D shape of the diffusion, providing informa-
tion about the magnitude and directionality of water diffu-
sion.83,87 DTI allows for the calculation of eigenvalues (λ) and 
quantification of tensor shapes, as well as the generation 
of a fractional anisotropy (FA) map.87Grade I meningiomas 
may have significantly lower FA, greater λ2 and λ3 values, 
and a greater proportion of spherical tensors compared 
with atypical meningiomas, indicating more disorganized 
microscopic water motion in grade I versus grade II men-
ingiomas.83 The authors of this particular study speculated 
that the histologic attributes of meningiomas accounted 
for these differences, with the whorls and fascicles found 
in grade I meningiomas serving as physical barriers to the 
linear movement of water molecules, with the sheet-like 
growth of atypical meningiomas possibly facilitating the dir-
ectional movement of water within the tumor.83
However, a later study using histogram analysis of 
DTI metrics to analyze differences between meningioma 
grades and subtypes found conflicting results.88 In this 
study, WHO grades II and III meningiomas had a signifi-
cantly reduced planar anisotropy coefficient along with 
histogram skewness measurements indicating a distribu-
tion shift toward a higher spherical anisotropy coefficient 
in comparison to their typical counterparts (grade I).88 An 
alternative explanation is that the loss of normal internal 
architecture seen in atypical meningiomas, such as the 
absence of whorls and fascicles in atypical meningiomas, 
results in less directionality in atypical meningiomas com-
pared with benign meningiomas.88
Perfusion Imaging
Perfusion imaging is a method for assessing the flow of 
blood occurring at the tissue level and is used frequently 
in neuro-oncologic imaging, particularly in the evaluation 
of gliomas.89,90 Prior studies assessing meningiomas with 
MR perfusion have successfully demonstrated a correl-
ation between cerebral blood volume (CBV) and histo-
logic measures of tumor vascularity, including microvessel 
density and area.91,92 A significant correlation between CBV 
and expression of vascular endothelial growth factor has 
been observed, suggesting that perfusion imaging may 
help to identify those meningiomas that may be refractory 
to conventional treatment and respond best to anti-angio-
genic therapies.93 In addition to correlation with vascular-
ity, maximum rCBV has been shown to positively correlate 
with the Ki-67 proliferative index in meningiomas.79
While correlation between perfusion values and vas-
cularity has been demonstrated, correlation between 
perfusion values and meningioma grade has had mixed 
results. Several studies found no statistically signifi-
cant difference in blood volume measures between typ-
ical/benign and atypical/malignant meningiomas.94–96 
Others, however, reported significant differences in 
rCBV, although with conflicting results. In a study of 24 
low-grade and 24 high-grade meningiomas, normalized 
maximum CBV ratios were higher in high-grade men-
ingiomas compared with low-grade meningiomas.93 In 
contrast, others have reported that the rCBV of benign 
meningiomas may be significantly higher than that of 
malignant meningiomas.92 The authors in the latter study 
hypothesized that malignant meningiomas might be in 
a state of relative ischemia and hypoxia because of their 
rapid growth, leading to a reduction in the number of 
tumor microvessels and a subsequent decrease in rCBV.92 
Evaluation of mean rCBV values in the peritumoral edema 
revealed that the maximal rCBV in the peritumoral edema 
was higher in malignant versus benign meningiomas.96 
This observation suggests that the increase in rCBV in the 
peritumoral edema of malignant meningiomas might be 
attributed to tumor invasion and angiogenesis in the adja-
cent brain tissue.96
Unlike intra-axial tumors, meningiomas typically derive 
blood supply from extracranial arteries which do not con-
tain a blood–brain barrier and are therefore permeable to 
contrast material. Therefore, meningiomas are generally 
associated with increased vascular permeability, and the 
impact of gadolinium contrast leakage on perfusion meas-
urements can be substantial using the DSC technique. This 
effect may have led to the mixed results of tumor grade 
prediction using the DSC method reported in the literature. 
DCE perfusion technique allows evaluation of vascular per-
meability directly. The Ktrans values measured by DCE were 
higher in atypical meningiomas compared with benign 
meningiomas, and the difference may reflect increased 
capillary leakiness due to micronecrosis in the high-grade 
tumors.95 Arterial-spine-labeling MR perfusion, a tech-
nique that can provide regional flow information without 
the confounding permeability factor and does not require 
gadolinium contrast, also has been shown to differen-
tiate WHO grade I from WHO grades II and III intracranial 
meningiomas.27
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Machine Learning and Radiomics
Radiomics, a field of quantitative imaging focused on con-
verting large sets of digital medical images into minable 
high-dimensional data, is of increasing interest in neuro-
oncology. These large image datasets, which include a var-
iety of imaging features, can offer information on imaging 
phenotype that can be used in conjunction with clinical 
information and correlated with clinical outcomes.97 In 
practice, 2 types of imaging features can be extracted—
“semantic” and “agnostic.”97 Semantic features are those 
that are visually assessed by the radiologist, such as bone 
invasion or necrosis, and as such, are subject to interob-
server variability.9,97 In contrast, agnostic features assess 
lesion heterogeneity through quantitative descriptors, 
such as skewness and texture.97
Radiomic analysis of the preoperative T1-weighted post-
contrast MRI features across 175 meningiomas revealed 
both quantitative and qualitative features that signifi-
cantly associated with meningioma grade, with high-grade 
tumors exhibiting more necrosis or hemorrhage, intra-
tumoral heterogeneity, nonspherical shape, and larger 
volumes.9 Intriguingly, quantitative radiomic features 
demonstrated significant association with number of atyp-
ical features among grade I  meningiomas, suggesting 
that further development of computational methods may 
afford detailed insights into meningioma biology beyond 
current capabilities.9 An additional study hypothesized that 
tumor heterogeneity and irregular shape may aid in men-
ingioma grading given their association with higher tumor 
grade, and observed several texture and shape features 
that contributed to the prediction of meningioma grade.98 
Furthermore, combination of quantitative and qualita-
tive analyses may provide synergistic capability to pre-
dict meningioma grade and behavior, opening venues for 
future exploration.9
Positron Emission Tomography
Although PET does not play a major role in the primary 
diagnosis of meningiomas, PET imaging may be helpful 
for treatment stratification and precise delineation of men-
ingioma, as well as in differentiating between viable tumor 
and scar tissue. Studies assessing the ability of FDG PET to 
differentiate meningioma grade have shown mixed results. 
The ratio of tumor to gray matter in atypical/malignant 
meningiomas has been shown to be higher than that in 
low-grade tumors and correlated with proliferative poten-
tial of the tumor, as well as being a significant predictor 
for tumor recurrence, although the sensitivity for detecting 
high-grade meningioma was only 43%.38 Additional stud-
ies have also shown the ability of FDG-PET to differentiate 
benign and atypical/malignant meningiomas,99,100 as well 
as to be able to differentiate recurrent or growing menin-
giomas from static meningiomas.101 However, opposite 
results have been reported to show a lack of correlation 
between FDG uptake and WHO grading, MIB-1 labeling 
index, or tumor doubling time.102–104
Another retrospective analysis demonstrated that high 
SSTR expression assessed by SUV measurements with 
PET correlated with higher tumor growth rate in WHO 
grades I  and II meningiomas, thus providing additional 
information beyond morphology that might be useful for 
patient treatment stratification.105
Summary of preoperative meningioma grade prediction
To date, histologic grades of meningiomas have been 
correlated to qualitative and quantitative features of 
many conventional and advanced imaging techniques, 
although most of these imaging markers, apart from 
those with obvious signs of brain invasion, are not used 
in routine clinical care, since they do not provide suffi-
ciently high accuracy for determination of tumor grade. 
For example, incidentally discovered meningiomas still 
require follow-up imaging to determine their prolifera-
tive characteristics, which would then influence the deci-
sion for the need of treatment and if so, the timing and 
type of treatment. Recent advances in radiomic technique 
combined with machine learning algorithms provide 
a pathway for improving the accuracy in tumor grade 
prediction, and the accuracy of radiomic tumor grading 
models will also be enhanced by advancement of novel 
imaging techniques.
Beyond Histopathologic Grade
While tumor grade is important in providing population-
based risk stratification, histopathologic grade does not 
always reliably predict which patients will progress or 
recur after treatment.106 The fact remains that sometimes 
high-grade tumors behave less aggressively and low-
grade tumors more aggressively.106,107 In addition, histo-
pathologic grading is often based on examination of only a 
limited sample of tissue, which can be a potential issue in 
more heterogeneous lesions, whereas imaging can more 
easily evaluate the entirety of the lesion.
Given this potential limitation of histopathologic grad-
ing, identification of imaging biomarkers able to provide 
prognostic information independently of histologic tumor 
grade is also of clinical importance, as it may offer com-
plementary information allowing for more individualized 
prognostic information and therapeutic recommenda-
tions. One recent study assessed the ability of preopera-
tive imaging and clinical characteristics to stratify patients 
based on risk for disease progression or recurrence follow-
ing initial treatment.106 That study found that the combin-
ation of extent of resection and ADC values outperformed 
WHO histopathologic grade for predicting which patients 
will suffer progression/recurrence after initial treatment. 
Similarly, preoperative radiological classification was able 
to supplement WHO histopathologic grading to accur-
ately predict the aggressive behavior of convexity menin-
giomas in another study.108 These may eventually lead to 
incorporation of imaging into the preoperative grading of 
meningiomas.
Summary
Preoperative MR and PET imaging are increasingly appre-
ciated to provide information regarding differential diagno-
sis, extent of tumor, and histologic grade of meningioma. 
Quantitative analytical methods are further augmenting 
the interpretation of imaging data and helping to correlate 
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imaging features with clinical outcome. Continued inves-
tigation is needed to further validate and refine these 
imaging biomarkers as well as to develop strategies of 
how to integrate these imaging methods into clinical prac-
tice. However, it is becoming increasingly evident that 
imaging will play a key role in further individualizing care 
for patients with meningiomas, both in managing patient 
expectations and in guiding therapy.
Imaging Considerations for 
Meningioma Treatment Planning
Surgical Planning Considerations
The operative strategy for meningiomas is influenced by 
the tumor location, its relationship with adjacent structures, 
the vascular supply to the tumor and the surgical corri-
dor, the anticipated tumor consistency, and the interface 
between tumor and brain—all of which can be appreciated 
with increasing clarity with imaging. The most common pre-
operative study for meningioma treatment planning is a 
contrast enhanced MRI, which aptly delineates the size, loca-
tion, heterogeneity, and vascularity of the tumor, as well as 
important features that influence the planning of the crani-
otomy and resection, such as peritumoral edema and extent 
of dural involvement. Conventional MRI, as well as advanced 
sequences such as MR elastography (MRe), may also sug-
gest the consistency and the nature of the tumor–brain 
interface by the extent of tumor nodularity at its boundary 
or a CSF cleft between the tumor and the surrounding par-
enchyma, the presence or absence of which may alter the 
surgical strategy. Bony involvement by meningioma may 
manifest as either erosion or hyperostosis and is best appre-
ciated on CT. Visualization of affected bone not only suggests 
the point of origin of the meningioma but is also important 
to recognize to ensure total removal of potentially invasive 
tumor cells for long-term disease control, as removal of bulk 
tumor, involved dura, and affected bone remains one of the 
most powerful influences on preventing recurrence in men-
ingioma.109 SSTR-PET can add valuable information to plan 
the extent of resection especially. Specific considerations 
and imaging modalities are detailed below.
Vascularity
Keen awareness of vasculature is critical to treatment plan-
ning for a presumed meningioma. First, the extent and 
source of vascular supply to meningioma dictates the surgi-
cal approach and preoperative consideration for emboliza-
tion. Early devascularization is a critical step in surgery for 
meningioma and promotes the ease of resection while mini-
mizing blood loss. Meningiomas derive their major blood 
supply from branches of the external carotid artery or men-
ingeal branches of the internal carotid and vertebrobasilar 
arteries, which may be clearly visualized on MRI, CT angiog-
raphy (CTA), or catheter-based angiography. In general, con-
vexity, parasagittal, and sphenoid wing meningiomas are 
primarily supplied by middle meningeal artery branches; 
olfactory groove meningiomas are supplied by branches 
of the ethmoidal arteries along with dural branches of the 
internal carotid artery. Lateral posterior fossa meningiomas 
are generally supplied by branches of the occipital and 
ascending pharyngeal artery, whereas posteromedial pos-
terior fossa meningiomas are typically fed by meningeal 
branches of the vertebral artery and the posterior meningeal 
artery. By nature of their central anatomical location, clival 
and tentorial meningiomas may receive their blood supply 
from various feeders such as the tentorial artery, cavernous 
internal carotid artery, and middle meningeal artery.
 For hypervascular meningiomas, branches that are dif-
ficult to reach during the exposure may be important to 
recognize and consider for preoperative embolization. 
On occasion, abundant intratumoral vascularity in an 
extra-axial intracranial tumor may suggest a diagnosis 
of hemangiopericytoma, rather than meningioma, which 
mandates a surgical technique that avoids precipitating 
significant intraoperative blood loss and possible pre-
operative embolization. Additionally, dynamic CT angio-
gram/venogram (dCTA/V) offers visualization of arterial 
and venous flow in a time- and phase-resolved fashion, 
similar to catheter angiography, and provides a unique 
vantage point in preoperative planning of skull base or 
paravenous meningiomas.8
Second, delineation of traversing vessels which pass 
through or along the surface of the tumor to supply nor-
mal brain rather than the tumor itself is important to avoid 
intra- and postoperative ischemia. This may be appreci-
ated on T2-weighted and postcontrast T1-weighted MRI 
sequences or CTA, which allow for visualization of the 
tumor mass in relation to the vessels. Prominent curvilin-
ear signal void or enhancement within or surrounding the 
tumor mass may suggest high tumor vascularity, and the 
intra- or peritumoral vascular anatomy including presence 
of thrombosis can be delineated using an imaging modality 
with temporal resolution, such as dCTA, MR angiography, 
or catheter angiography. Distinction between a high-flow 
state versus intraluminal thrombosis is important to dis-
tinguish before venturing into tumor debulking (Figure 4). 
Preservation of en passage vessels is also critical to avoid 
unintentional ischemia in the surrounding brain.
Third, clear appreciation of partial or complete venous 
sinus occlusion, as well as the course of venous rerout-
ing along the periphery of sinus-invasive meningiomas, 
influences the operative strategy and preparation for sinus 
reconstruction or avoidance with use of a staged surgery 
and radiosurgery approach.110,111 While catheter-based 
angiography affords the highest specificity and sensitivity 
in determining sinus patency, its cost and risk, albeit low, 
decrease its utility compared with less invasive modali-
ties. CT venogram (CTV) and MR venogram (MRV) are fre-
quently performed in this context, with varying sensitivity 
and specificity. In comparison, dCTA/V provides 3D flow-
dependent resolution of venous sinuses and alternative 
venous channels, allowing for the advantage of catheter-
based angiography in a non-invasive test.
Tracts and nerves
As extrinsic tumors which arise from outside the brain 
parenchyma, meningiomas classically displace rather 
than disrupt or infiltrate into adjacent white matter 
tracts. For meningiomas abutting the corticospinal tract, 
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reduction in diffusion tensor tractography fiber number 
and density, but not deviation, correlated with postop-
erative temporary paresis in one study.112 While such 
imaging analysis suggests a means for risk stratification 
in meningioma surgery, it does not obviate the contri-
bution of surgical influences on postoperative function, 
including technique, presence, and treatment of the 
arachnoid plane around the meningioma, and extent of 
traction during tumor resection. Tractography has also 
been applied to resolve the course of cranial nerves 
from their nucleus of origin to foramen of exit, as well 
as the optic chiasm and pathway, in relation to skull base 
tumors; however, this is subject to distortion by large 
tumors and the computational algorithms applied to 
resolve the tracts. Among conventional MRI sequences, 
cranial nerves within cisternal spaces are best appreci-
ated on high-resolution CSF-sensitive sequences such 
as constructive interference in steady state (CISS), with 
their identification critical in planning safe resection of 
skull base meningiomas.
Tumor consistency
The texture of meningiomas, especially those at the cra-
nial base or which surround neurovascular structures, 
influences the complexity, time, and risk during surgery for 
meningioma; it is among the most critical of surgical vari-
ables and can be very difficult to ascertain preoperatively 
from imaging alone. Soft lesions are more amenable to 
suction aspiration than are tough, fibrous lesions; should 
firm lesions surround vessels and/or nerves, it may be far 
more challenging to dissect these normal structures.
On conventional MRI, meningioma hyperintensity on 
T2-weighted images and hypointensity on T1-weighted 
images serve as a surrogate for softer texture, while 
T2-weighted hypointensity suggests firmer tumor, 
although the predictive value can be inconsistent.113,114 
Additionally, the association of DWI with meningioma tex-
ture has been variable, with high FA values, hyperintensity 
on FA maps, and isointensity on mean diffusivity maps 
suggestive of firmer texture in some studies.114,115
Complementary to anatomic imaging, MRe is a devel-
oping technology which shows promise in determining 
tumor firmness and its relationship with adjacent struc-
tures.116 Specifically, MRe captures the tissue response 
after delivering a source of motion and then mathemat-
ically calculates a viscoelastic model that estimates firm-
ness. Differing stiffness on either side of a tissue boundary 
generates a “slip” interface, or a measurement of the free-
dom with which adjacent tissue planes can slide past one 
another and create an estimate of marginal invasiveness. 
In clinical series of meningioma which underwent surgical 
resection, prediction of tumor firmness by MRe correlated 
with intraoperative observations in two-third of cases, with 
greater error for vascular and small tumors.117 Shear line 
and octahedral shear strain (OSS) values derived from 
MRe sequences concurred with intraoperative annotation 
of tumor adhesion with the brain in 72% of cases, while 
normalized OSS values offered over 90% concordance 
with surgical observations.118 Note that MRe is suboptimal 
in the evaluation of small meningiomas given its limited 
spatial resolution.
Imaging Considerations for Radiation Therapy
MRI and CT play a tantamount role in demarcation of men-
ingiomas for radiation planning. While tumor bulk and 
dural involvement are well appreciated on gadolinium-
enhanced T1 MRI, fat-saturation sequences are particu-
larly useful for delineation of meningioma boundaries 
at the skull base and abutting venous sinuses. Thin-slice 
3D views, especially the coronal plane, are important for 
fine separation of optic apparatus, brainstem, and other 
sensitive structures during treatment plan contouring. 
Tractography and high-resolution CSF-sensitive sequences 
such as CISS can also be critical in helping identify cranial 
nerves during planning.
Molecular Imaging and Targeted Therapy 
Considerations
Regarding meningioma delineation, several different tis-
sues are to be respected as background (eg, brain, bone, 
blood; in the case of pretreated lesions, fibrotic tissue). 
Due to usually high levels of glucose in healthy brain par-
enchyma causing a poor tumor-to-background contrast, 
the tracer 18F-FDG is not suitable for precise tumor delinea-
tion.119 In contrast, because of its high specificity, SSTR-PET 
can add valuable information to plan the extent of resec-
tion. Especially in tumors with transosseous growth and 
complex location and in pretreated lesions, sensitivity and 
specificity are higher compared with MRI (Supplementary 
Figure 2). Thus, the surgeon can tailor the resection more 
accordingly. Integration of PET imaging into neuronaviga-
tion systems allows for retrieval of this information even 
without additional intraoperative imaging.120 Similarly, 
precision of targeting radiation can be improved especially 
in pretreated or transosseous lesions.121–123
Finally, the first centers are currently investigating the 
therapeutic approach with DOTA-conjugated SSTR ligands 
in “out-treated” meningioma patients under progression 
after several lines of therapy.124–127 Because the same SSTR 
ligand can either be radiolabeled with the positron emitter 
Ga-68 for PET imaging or with the ß-emitters lutetium-177 
and yttrium-90 for peptide receptor radionuclide therapy 
(PRRT), semi-quantitative SSTR-PET measurement prior to 
PRRT is considered to be crucial for an adequate patient 
selection, since higher SSTR expression as measured by 
PET was shown to be associated with higher radiation dose 
in the tumor.128 Even more, tracer uptake and response 
correlated in patients with multiple lesions.129
Posttreatment Imaging Considerations
Postsurgical Artifacts to Consider on 
Conventional MRI
When achievable, total surgical resection (Simpson grade 
1)  is associated with lower recurrence and longer overall 
survival (OS) for benign, atypical, and malignant meningi-
omas.130–132 Besides providing prognostic value, extent of 
resection also provides predictive value for early adjuvant 
radiation treatment of atypical meningioma, since there is no 
D
ow
nloaded from
 https://academ
ic.oup.com
/neuro-oncology/article-abstract/21/Supplem
ent_1/i44/5289368 by johns hopkins university user on 03 July 2019
 i56 Huang et al. Imaging advances in meningiomas
benefit of survival or recurrence for patients with gross total 
surgical resection (Simpson grades 1–3) of those tumors.133 
Evaluation of residual meningioma is most commonly 
done on contrast enhanced MRI performed within 24–72 
hours after surgery. After 72 hours, contrast enhancement 
from granulation tissues at the resection site often begins 
to develop, making it difficult to distinguish from residual 
tumor.134 More recently, presence of non–tumor related react-
ive enhancement can be detected between 48 and 72 hours 
on 3T MRI,135,136 although reactive changes tend to appear 
linear, while residual tumor enhancement is often nodular.136 
Novel radiotracer imaging such as 68Ga-DOTATATE PET 
appears to be more specific for residual meningioma and 
can be considered when MRI is equivocal.137,138
During the immediate postoperative period, significant 
susceptibility artifact is common due to the presence of air 
and blood product at the resection site obscuring sites of 
enhancing tumor. To reduce susceptibility artifact related to 
surgery or at locations near the skull base, 3D spin echo 
MR technique is preferred over 3D gradient echo tech-
niques.139 It is advantageous to apply a fat-suppression 
technique to the acquisition pulse sequence to distinguish 
enhancing tissues from fat graft material. Fat suppression 
also allows delineation of tumor from marrow or extracra-
nial fat if meningiomas extend to the calvarium, skull base, 
or extracranial structures.
Posttreatment Follow-Up Guidelines
Even though MRI is routinely performed for following 
meningiomas after surgery, radiation, or systemic ther-
apy, consensus for the frequency of imaging follow-up is 
lacking. Moreover, the degree of progression or growth 
of residual tumor that is clinically relevant to initiate a sec-
ond therapeutic intervention is not known. The National 
Comprehensive Cancer Network provides a guideline for 
monitoring WHO grades I and II meningiomas at 3, 6, and 
12  months after initial surgery or radiation, followed by 
every 6–12 months for 5 years, and then every 1–3 years as 
clinically indicated (NCCN version 1.2018). However, menin-
giomas tend to exhibit delayed recurrence on the order of 
10 to 20 years,109 and require long-term vigilance in a young 
patient. For WHO grade III meningiomas, and for meningi-
omas of any grade that are treated for recurrence or with 
chemotherapy, more frequent imaging may be necessary 
and may depend on symptoms and expected risk of recur-
rence. One challenge in defining optimal follow-up imaging 
frequency for meningiomas is the variability in their growth 
trajectories. In one series, atypical meningiomas grew expo-
nentially, while benign meningiomas exhibited exponential, 
linear, or no growth.140 For benign meningiomas, a sig-
moid growth curve has been used to model the alteration 
of growth pattern over time for meningiomas that eventu-
ally slow or stop growing.141 For this group of patients, less 
frequent imaging may be appropriate once the growth rate 
appears to plateau. Slowing of growth rate has been associ-
ated with the appearance of intratumoral calcification.140 For 
meningiomas that grow exponentially, the period of acceler-
ated growth is associated with increase in the Ki-67 prolif-
erative index.142 It has been shown that tumor ADC values 
on DWI are associated with Ki-67 index,143 and meningiomas 
with low ADC are also at significantly increased risk of recur-
rence.106,144  This marker may potentially be used to monitor 
tumor proliferation over time. As a general rule, surveillance 
imaging schemes after surgery vary based on the perceived 
risk of recurrence, with regrowth firmly predicated on inher-
ent biological tumor characteristics (eg, grade, MIB-1) and 
the completeness of surgical resection.131,145 Given that dis-
tinct DNA methylation signatures have been shown to iden-
tify distinct risk groups, it is possible that the frequency of 
surveillance imaging may ultimately be governed by the 
molecular alterations of a given tumor (see the Biomolecular 
Landscape paper elsewhere in this supplement).
Response Criteria for Clinical Trials of 
Meningiomas
Currently, no standard imaging criteria exist for deter-
mining response or progression in clinical trials of men-
ingioma. Variations of 1D (Response Evaluation Criteria In 
Solid Tumors)146 and 2D (Macdonald) criteria147 have been 
used in previous clinical trials, although these imaging 
criteria have been developed for clinical trials of systemic 
tumors and high-grade gliomas. Unlike in these cancers, 
OS is often very long for meningioma, and even progres-
sion-free survival requires long-term follow-up. To capture 
more tumors that exhibit small changes, the Response 
Assessment in Neuro-Oncology (RANO) Meningioma 
working group has proposed a modification of 2D crite-
ria to include a 25% reduction in dimensional product of 
tumor area as “minor response” (RANO Meningioma 
paper under review), which will need to be validated in 
future trials. In addition to 1D and 2D measurements, volu-
metric approach has been evaluated as response criteria 
for meningiomas (meningioma paper under review). Due 
to the often irregular contour of meningiomas that conform 
to the cranial vault or skull base, a volumetric approach is 
expected to be more accurate in depicting tumor burden 
than 1D or 2D cross-sectional measurements. Making 1D 
and 2D measurements can be quite variable in irregularly 
shaped tumors, and they may inadequately represent the 
size of irregular tumors. Since it is technically much more 
challenging to obtain tumor volume, this approach may 
not be easily implemented in clinical trials at the present 
and require more data in validating its advantage over 
cross-sectional methods.
Treatment Effect versus True Progression or 
Response
While radiation necrosis can be observed following radi-
ation therapy, and stereotactic radiosurgery in particu-
lar, for meningiomas, it is typically feasible to distinguish 
treatment effect from tumor on MRI, as the former will 
appear as intra-axial enhancement rather than as dural 
thickening or nodular enhancement observed with residual 
or recurrent meningiomas. In a small subset of atypical or 
malignant meningiomas with brain invasion, it can be chal-
lenging to discern tumor from treatment necrosis at the 
brain–tumor interface and requires serial MRI to determine 
growth of the enhancing regions.
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The anti-angiogenic agent bevacizumab has been evalu-
ated for treatment of meningiomas.148–150 Due to its effect 
on vascular permeability, bevacizumab can reduce the 
intensity of contrast enhancement within a tumor, a phe-
nomenon commonly observed among high-grade gliomas 
receiving this treatment. Since meningiomas are primar-
ily measured by the size of contrast enhancement, it is 
possible that perceived reductions in tumor burden could 
result from contrast enhancement suppression by treat-
ment rather than actual tumor shrinkage.
Perspectives on the Future of Imaging 
in the Management of Meningiomas
A multitude of imaging features based on CT, MRI, and nuclear 
medicine techniques show promising values in the clinical 
management of meningiomas, including diagnosis, grading, 
treatment planning, prognostication, and treatment monitor-
ing. These imaging markers are derived from novel methods 
of acquisition, postprocessing, and image feature extraction. 
Dual-energy CT has also been applied to differentiate menin-
giomas from pituitary adenomas of the sella/tuberculum.151 
High magnetic field scanners at 7T provide more detailed 
delineation of peritumoral vascularity and brain–tumor inter-
face that may facilitate surgical planning.152 Amide proton 
transfer imaging is a novel MRI method based on endogenous 
mobile proteins and peptides in tissue and has been applied 
to differentiate atypical meningiomas from benign meningi-
omas.153 In order for widespread clinical implementations of 
these imaging techniques, their accuracy and reproducibility 
need to be validated within well-defined patient populations, 
tumor subtypes, and treatment modalities.
While many imaging markers evaluated to date show 
correlations with biological characteristics of meningioma, 
patient outcome, or both, there is a significant degree of 
heterogeneity among the reported accuracies when they 
are used as diagnostic or prognostic makers. For example, 
reports on the use of low preoperative ADC to predict 
higher histological grade and greater risk of recurrence 
differed in their diagnostic performance and the threshold 
values for ADC. These differences can be due to variations 
in imaging acquisition and postprocessing method as well 
as patient selection. Other potential confounding factors 
include the effect of susceptibility from calcifications within 
tumors, which can alter ADC measurements.154 Since cal-
cification may be suggestive of meningiomas with more 
indolent clinical course, low ADC values resulting from cal-
cifications may result in misclassification of these tumors 
to higher grade and higher risk of recurrence.
PET imaging might gain further importance—however, 
more prospective multi-institutional studies for validation 
are in need. Therefore, technical guidelines for imaging 
acquisition and readout are necessary, which are currently 
being developed by the RANO-PET task force. Introduction 
of new, specific ligands/tracers might open new avenues 
for metabolic imaging in meningiomas.
Strategies that combine multiple imaging features 
to generate diagnostic and predictive markers are 
therefore more likely to provide a more comprehen-
sive assessment of tumor biology. Recent radiomic 
approaches in combination with machine learning algo-
rithms have been increasingly employed to generate 
and refine imaging markers.9 One major advantage of 
this approach is its ability to incorporate clinical, ana-
tomical, genomic features into a combined model. 
Due to inter-institutional variations of imaging acquisi-
tion equipment, imaging protocol, and postprocessing 
method, this approach requires a large sample size for 
model training to achieve high accuracy, and the result-
ant models also need to be validated for generalizability 
using independent datasets. A public database for men-
ingioma including imaging, clinical, and genomic data is 
urgently needed.
Conclusion
The central role of imaging in the contemporary treat-
ment and management of meningioma is in its descrip-
tive strength; its ability to inform location, growth over 
time, effect on adjacent tissues, and adjacency to critical 
structures, for instance, is vital. The predictive power of 
imaging, however, is in its infancy. With advances in our 
understanding of the fundamental biology of meningi-
oma, targeted and immunologic approaches are being 
developed and evaluated for treatment in recurrent dis-
ease to complement current standard approaches of sur-
gery and radiation therapy. In this era, imaging will be 
relied upon for the non-invasive determination of fac-
tors such as histologic grade and genetic constitution 
and, ultimately, for the prediction of tumor behavior, 
whose influence on management strategies cannot be 
underestimated.
Recommendations
With respect to advances in imaging and diagnosis, the 
International Consortium on Meningiomas recommends:
• Use of routine imaging modalities for diagnosis and sur-
veillance of meningiomas
• Use of standardized definition for tumor progression or 
recurrence (which will be established through the RANO 
working group) across all centers for both clinical and 
research use
• In cases where the certainty of recurrence or tumor pro-
gression is equivocal, advancing imaging modalities 
such as PET may be considered.
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